| scholarly article | Q13442814 |
| P2093 | author name string | Dori R Germolec | |
| Marina A Dobrovolskaia | |||
| James L Weaver | |||
| P2860 | cites work | Immunological properties of engineered nanomaterials | Q29615634 |
| Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties | Q35559623 | ||
| Issues with introducing new immunotoxicology methods into the safety assessment of pharmaceuticals | Q41453714 | ||
| Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics | Q44527207 | ||
| Evaluation of a lymph node proliferation assay for its ability to detect pharmaceuticals with potential to cause immune-mediated drug reactions | Q45242069 | ||
| Nanoparticles target distinct dendritic cell populations according to their size | Q45732404 | ||
| Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors | Q47409832 | ||
| The importance of an endotoxin-free environment during the production of nanoparticles used in medical applications. | Q51149770 | ||
| Exploiting lymphatic transport and complement activation in nanoparticle vaccines | Q81305052 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nanoparticle | Q61231 |
| P304 | page(s) | 411-414 | |
| P577 | publication date | 2009-06-28 | |
| P1433 | published in | Nature Nanotechnology | Q920399 |
| P1476 | title | Evaluation of nanoparticle immunotoxicity. | |
| P478 | volume | 4 |
| Q42972230 | A Liposome Encapsulated Ruthenium Polypyridine Complex as a Theranostic Platform for Triple-Negative Breast Cancer. |
| Q46037881 | A Proposed Computed Tomography Contrast Agent Using Carboxybetaine Zwitterionic Tantalum Oxide Nanoparticles: Imaging, Biological, and Physicochemical Performance. |
| Q30420026 | A hybrid protein-polymer nanoworm potentiates apoptosis better than a monoclonal antibody |
| Q52624382 | Accelerated Blood Clearance (ABC) Phenomenon Favors the Accumulation of Tartar Emetic in Pegylated Liposomes in BALB/c Mice Liver. |
| Q90278729 | Analysing the nanoparticle-protein corona for potential molecular target identification |
| Q34675068 | Analysis of the murine immune response to pulmonary delivery of precisely fabricated nano- and microscale particles |
| Q102053830 | Antibiofilm effects of N,O-acetals derived from 2-amino-1,4-naphthoquinone are associated with downregulation of important global virulence regulators in methicillin-resistant Staphylococcus aureus |
| Q42636559 | Are high drug loading nanoparticles the next step forward for chemotherapy? |
| Q47344188 | Bacterial endotoxin (lipopolysaccharide) binds to the surface of gold nanoparticles, interferes with biocorona formation and induces human monocyte inflammatory activation. |
| Q90080122 | Biodistribution and Biosafety of a Poly(Phosphorhydrazone) Dendrimer, an Anti-Inflammatory Drug-Candidate |
| Q53275631 | Biomedical nanoparticles modulate specific CD4+ T cell stimulation by inhibition of antigen processing in dendritic cells. |
| Q28481630 | Biosafety of non-surface modified carbon nanocapsules as a potential alternative to carbon nanotubes for drug delivery purposes |
| Q36814280 | Biotargeted nanomedicines for cancer: six tenets before you begin |
| Q34088840 | Body-on-a-chip simulation with gastrointestinal tract and liver tissues suggests that ingested nanoparticles have the potential to cause liver injury |
| Q99565147 | Carbon Quantum Dots: In vitro and in vivo Studies on Biocompatibility and Biointeractions for Optical Imaging |
| Q90180998 | Chitosan Nanoparticles: Shedding Light on Immunotoxicity and Hemocompatibility |
| Q39041437 | Choice of method for endotoxin detection depends on nanoformulation. |
| Q36403660 | Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory. |
| Q35526682 | Comparative proteomic analysis of the molecular responses of mouse macrophages to titanium dioxide and copper oxide nanoparticles unravels some toxic mechanisms for copper oxide nanoparticles in macrophages. |
| Q48114857 | Comparison of Avidin, Neutravidin, and Streptavidin as Nanocarriers for Efficient siRNA Delivery |
| Q36165414 | Conformational changes of fibrinogen in dispersed carbon nanotubes |
| Q50077998 | Considerations and Some Practical Solutions to Overcome Nanoparticle Interference with LAL Assays and to Avoid Endotoxin Contamination in Nanoformulations |
| Q26345204 | Current understanding of interactions between nanoparticles and the immune system |
| Q28383550 | Cytokines as biomarkers of nanoparticle immunotoxicity |
| Q30958719 | Data Mining as a Guide for the Construction of Cross-Linked Nanoparticles with Low Immunotoxicity via Control of Polymer Chemistry and Supramolecular Assembly |
| Q36202649 | Detection of Endotoxin Contamination of Graphene Based Materials Using the TNF-α Expression Test and Guidelines for Endotoxin-Free Graphene Oxide Production |
| Q30696294 | Developing Xenopus embryos recover by compacting and expelling single wall carbon nanotubes. |
| Q46988098 | Development and characterization of a new carrier for vaccine delivery based on calcium-alginate nanoparticles: Safe immunoprotective approach against scorpion envenoming |
| Q37381547 | Differential immunotoxicities of poly(ethylene glycol)- vs. poly(carboxybetaine)-coated nanoparticles |
| Q57367552 | Effects of thermosensitive poly(N-isopropylacrylamide) on blood coagulation |
| Q28071776 | Endotoxin contamination: a key element in the interpretation of nanosafety studies |
| Q58235087 | Exosomes as Extrapulmonary Signaling Conveyors for Nanoparticle-Induced Systemic Immune Activation |
| Q28384134 | From immunotoxicity to nanotherapy: the effects of nanomaterials on the immune system |
| Q90359981 | Genotoxicity of amorphous silica nanoparticles: Status and prospects |
| Q37775971 | Glyconanoparticles: multifunctional nanomaterials for biomedical applications. |
| Q39629887 | Gold nanoparticle trafficking of typically excluded compounds across the cell membrane in JB6 Cl 41-5a cells causes assay interference |
| Q39519805 | Gold nanoparticle-mediated gene delivery induces widespread changes in the expression of innate immunity genes. |
| Q39403516 | Graphene and the Immune System: A Romance of Many Dimensions |
| Q38026064 | Heat shock proteins are therapeutic targets in autoimmune diseases and other chronic inflammatory conditions |
| Q59217817 | Human monocyte response to Andean-native starch nanoparticles |
| Q28384347 | Identification and avoidance of potential artifacts and misinterpretations in nanomaterial ecotoxicity measurements |
| Q35839945 | Identifying new therapeutic targets via modulation of protein corona formation by engineered nanoparticles |
| Q36427935 | Immune cell impact of three differently coated lipid nanocapsules: pluronic, chitosan and polyethylene glycol |
| Q33578950 | Immunological properties of gold nanoparticles |
| Q27005267 | Immunosuppressive and anti-inflammatory properties of engineered nanomaterials |
| Q90581271 | Immunotoxicity Considerations for Next Generation Cancer Nanomedicines |
| Q28388540 | Impact of carbon nanotubes and graphene on immune cells |
| Q50459468 | Impact of graphene oxide on the structure and function of important multiple blood components by a dose-dependent pattern |
| Q28950905 | In Vivo Toxicity Studies of Metal and Metal Oxide Nanoparticles |
| Q34316255 | In vivo evaluation of safety of nanoporous silicon carriers following single and multiple dose intravenous administrations in mice |
| Q34158423 | In vivo immunotoxicity of SiO2@(Y0.5Gd0.45Eu0.05)2O3 as dual-modality nanoprobes |
| Q33574182 | Influence of surface chemistry on cytotoxicity and cellular uptake of nanocapsules in breast cancer and phagocytic cells |
| Q90225928 | Inhibition of Pore-Forming Proteins |
| Q38222429 | Inorganic Nanoparticles for Therapeutic Delivery: Trials, Tribulations and Promise |
| Q37970755 | Interaction of nanoparticles with immunocompetent cells: nanosafety considerations |
| Q47942103 | Interference of silica nanoparticles with the traditional Limulus amebocyte lysate gel clot assay |
| Q39282155 | Intradermal air pouch leukocytosis as an in vivo test for nanoparticles |
| Q41915826 | Materials design at the interface of nanoparticles and innate immunity. |
| Q77791988 | Metal nanomaterials: immune effects and implications of physicochemical properties on sensitization, elicitation, and exacerbation of allergic disease |
| Q59138158 | Metallic Nanoparticles: General Research Approaches to Immunological Characterization |
| Q50078035 | Methods for Analysis of Nanoparticle Immunosuppressive Properties In Vitro and In Vivo |
| Q34435740 | Microfluidic technologies for accelerating the clinical translation of nanoparticles |
| Q37289373 | Molecular responses of mouse macrophages to copper and copper oxide nanoparticles inferred from proteomic analyses. |
| Q34276290 | Multifunctional gold nanorods for siRNA gene silencing and photothermal therapy |
| Q36641483 | Nano-titanium dioxide modulates the dermal sensitization potency of DNCB. |
| Q30596905 | Nanoamplifiers synthesized from gadolinium and gold nanocomposites for magnetic resonance imaging |
| Q38418305 | Nanomaterials for enhanced immunity as an innovative paradigm in nanomedicine. |
| Q28395287 | Nanoparticle Uptake: The Phagocyte Problem |
| Q36760929 | Nanoparticle size and surface charge determine effects of PAMAM dendrimers on human platelets in vitro |
| Q28390761 | Nanoparticle toxicity by the gastrointestinal route: evidence and knowledge gaps |
| Q50099761 | Nanoparticle-Based Strategies to Treat Neuro-Inflammation. |
| Q58235089 | Nanoparticle-Induced Exosomes Target Antigen-Presenting Cells to Initiate Th1-Type Immune Activation |
| Q27000646 | Nanoparticle-based monitoring of cell therapy |
| Q28651643 | Nanoparticles for cancer imaging: The good, the bad, and the promise |
| Q36921377 | Nanoscale Semiconductor Devices as New Biomaterials. |
| Q28069635 | Nanosized Drug Delivery Systems in Gastrointestinal Targeting: Interactions with Microbiota |
| Q34089324 | Nanotargeted radionuclides for cancer nuclear imaging and internal radiotherapy |
| Q37835204 | Nanotoxicology: an interdisciplinary challenge |
| Q38364473 | No king without a crown--impact of the nanomaterial-protein corona on nanobiomedicine |
| Q92152176 | Nucleic Acid Nanoparticles at a Crossroads of Vaccines and Immunotherapies |
| Q58742973 | Optimising the use of commercial LAL assays for the analysis of endotoxin contamination in metal colloids and metal oxide nanoparticles |
| Q34071603 | PLGA, PLGA-TMC and TMC-TPP nanoparticles differentially modulate the outcome of nasal vaccination by inducing tolerance or enhancing humoral immunity |
| Q58073566 | Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a ‘mixed matrix’ |
| Q39021861 | Particulate nature of inhaled zinc oxide nanoparticles determines systemic effects and mechanisms of pulmonary inflammation in mice |
| Q39262135 | Pharmaceutical differences between block copolymer self-assembled and cross-linked nanoassemblies as carriers for tunable drug release |
| Q91912625 | Physalis Mottle Virus-like Nanoparticles for Targeted Cancer Imaging |
| Q64939011 | Poly(D,L-Lactic Acid) Nanoparticle Size Reduction Increases Its Immunotoxicity. |
| Q28081577 | Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy |
| Q41667031 | Pro-Inflammatory Versus Anti-Inflammatory Effects of Dendrimers: The Two Faces of Immuno-Modulatory Nanoparticles. |
| Q57364539 | Protein binding to soft polymeric layers: a quantitative study by fluorescence spectroscopy |
| Q48285696 | Quantitative profiling of the protein coronas that form around nanoparticles |
| Q39093144 | Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology |
| Q59134586 | Regulatory Aspects of Oncologicals: Nanosystems Main Challenges |
| Q44989507 | Route-dependent systemic and local immune effects following exposure to solutions prepared from titanium dioxide nanoparticles. |
| Q38219592 | Scale of health: indices of safety and efficacy in the evolving environment of large biological datasets |
| Q39022221 | Size-dependent effect of zinc oxide on toxicity and inflammatory potential of human monocytes. |
| Q37841416 | Standardization of models and methods used to assess nanoparticles in cardiovascular applications |
| Q39052191 | Surface functionalized mesoporous silica nanoparticles with natural proteins for reduced immunotoxicity |
| Q35882643 | Switching the targeting pathways of a therapeutic antibody by nanodesign |
| Q89719175 | Synthesis and Cytotoxicity Studies on Ru and Rh Nanoparticles as Potential X-Ray Fluorescence Computed Tomography (XFCT) Contrast Agents |
| Q35792897 | Targeted Imaging and Therapy of Brain Cancer Using Theranostic Nanoparticles |
| Q38292678 | The Effects of Spacer Length and Composition on Aptamer-Mediated Cell-Specific Targeting with Nanoscale PEGylated Liposomal Doxorubicin. |
| Q38616577 | The Molecular Influence of Graphene and Graphene Oxide on the Immune System Under In Vitro and In Vivo Conditions. |
| Q28085280 | The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery |
| Q35657508 | The rational design of a synthetic polymer nanoparticle that neutralizes a toxic peptide in vivo |
| Q36807868 | The role of surface functionality in determining nanoparticle cytotoxicity |
| Q34030504 | Thermophysical and biological responses of gold nanoparticle laser heating |
| Q38379927 | Towards a nanospecific approach for risk assessment |
| Q34110059 | Toxicity evaluation of Gd2O3@SiO2 nanoparticles prepared by laser ablation in liquid as MRI contrast agents in vivo |
| Q30708177 | Ultrahigh relaxivity and safe probes of manganese oxide nanoparticles for in vivo imaging |
| Q55407149 | Understanding and Characterizing Functional Properties of Nanoparticles |
| Q38112504 | Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines |
| Q39654668 | Uptake of gold nanoparticles in murine macrophage cells without cytotoxicity or production of pro-inflammatory mediators |
| Q42427526 | Using the air pouch model for assessing in vivo inflammatory activity of nanoparticles |
| Q28084932 | Value of phagocyte function screening for immunotoxicity of nanoparticles in vivo |
Search more.